---
title: Apraclonidine
description: >-
  Apraclonidine is prescribed for the short-term treatment of elevated
  intraocular pressure (IOP) in patients with glaucoma on maximally tolerated
  medical therapy who require an additional IOP reduction to delay laser
  trabeculoplasty or other glaucoma surgery. It is also used to prevent or
  control ...
is_banned: false
lastModified: '2025-09-22T17:21:52.225Z'
faqs:
  - q: >-
      What is the recommended dosage for Apraclonidine?


      A: For glaucoma: 1-2 drops of 0.5% solution three times daily in the
      affected eye(s) for a maximum of one month. For perioperative use: One
      drop of 1% solution one hour before and immediately after anterior segment
      laser surgery.
    a: >-
      A: For glaucoma: 1-2 drops of 0.5% solution three times daily in the
      affected eye(s) for a maximum of one month. For perioperative use: One
      drop of 1% solution one hour before and immediately after anterior segment
      laser surgery.
  - q: >-
      What is the mechanism of action of Apraclonidine?


      A: Apraclonidine primarily reduces intraocular pressure by decreasing
      aqueous humor production through its action as an alpha-2 adrenergic
      agonist.
    a: >-
      A: Apraclonidine primarily reduces intraocular pressure by decreasing
      aqueous humor production through its action as an alpha-2 adrenergic
      agonist.
  - q: >-
      What are the common side effects of Apraclonidine?


      A: Common side effects include dry eyes, blurred vision, foreign body
      sensation, dry mouth, drowsiness, dizziness, headache, and fatigue.
    a: >-
      A: Common side effects include dry eyes, blurred vision, foreign body
      sensation, dry mouth, drowsiness, dizziness, headache, and fatigue.
  - q: >-
      What are the contraindications for Apraclonidine use?


      A: Apraclonidine is contraindicated in patients with hypersensitivity to
      the drug or clonidine, and in those concurrently taking monoamine oxidase
      inhibitors (MAOIs).
    a: >-
      A: Apraclonidine is contraindicated in patients with hypersensitivity to
      the drug or clonidine, and in those concurrently taking monoamine oxidase
      inhibitors (MAOIs).
  - q: >-
      Are there any drug interactions with Apraclonidine?


      A: Yes.  Apraclonidine can interact with other IOP-lowering medications,
      clonidine, CNS depressants, beta-blockers, cardiac glycosides, and
      tricyclic antidepressants.
    a: >-
      A: Yes.  Apraclonidine can interact with other IOP-lowering medications,
      clonidine, CNS depressants, beta-blockers, cardiac glycosides, and
      tricyclic antidepressants.
  - q: >-
      Can Apraclonidine be used during pregnancy or breastfeeding?


      A: Apraclonidine is generally not recommended during pregnancy or
      breastfeeding due to potential risks to the fetus or infant.
    a: >-
      A: Apraclonidine is generally not recommended during pregnancy or
      breastfeeding due to potential risks to the fetus or infant.
  - q: >-
      What are the signs of an allergic reaction to Apraclonidine?


      A: Allergic reactions can manifest as itching, rash, hives, swelling of
      the face or throat, difficulty breathing, and severe dizziness. Seek
      immediate medical attention if these occur.
    a: >-
      A: Allergic reactions can manifest as itching, rash, hives, swelling of
      the face or throat, difficulty breathing, and severe dizziness. Seek
      immediate medical attention if these occur.
  - q: >-
      What should patients be advised regarding activities requiring mental
      alertness while using Apraclonidine?


      A: Apraclonidine can cause drowsiness and dizziness.  Patients should be
      cautioned about engaging in activities that require mental alertness, such
      as driving or operating machinery, until the effects of the medication are
      known.
    a: >-
      A: Apraclonidine can cause drowsiness and dizziness.  Patients should be
      cautioned about engaging in activities that require mental alertness, such
      as driving or operating machinery, until the effects of the medication are
      known.
  - q: >-
      How should Apraclonidine be stored?


      A: Store apraclonidine ophthalmic solution below 25°C (77°F). Do not
      freeze. Protect from light.  Discard any unused medication after the
      expiration date or four weeks after opening.
    a: >-
      A: Store apraclonidine ophthalmic solution below 25°C (77°F). Do not
      freeze. Protect from light.  Discard any unused medication after the
      expiration date or four weeks after opening.
---
## Usage

Apraclonidine is prescribed for the short-term treatment of elevated intraocular pressure (IOP) in patients with glaucoma on maximally tolerated medical therapy who require an additional IOP reduction to delay laser trabeculoplasty or other glaucoma surgery. It is also used to prevent or control IOP elevation after anterior segment laser surgery.  It is classified as an ophthalmic alpha-2 adrenergic agonist.  Apraclonidine primarily works by decreasing aqueous humor production, which lowers IOP.

## Alternate Names

Apraclonidine hydrochloride is the chemical name.  A common brand name is Iopidine.

## How It Works

**Pharmacodynamics:** Apraclonidine is a relatively selective alpha-2 adrenergic agonist with some alpha-1 activity. Its primary ocular hypotensive effect results from decreased aqueous humor production. While minimal membrane stabilizing activity exists, it doesn't significantly contribute to its IOP-lowering mechanism.

**Pharmacokinetics:** Apraclonidine is administered topically as an ophthalmic solution.  Onset of action typically occurs within one hour, with peak IOP reduction at approximately 3-5 hours post-instillation.  Systemic absorption is minimal, resulting in low plasma concentrations, typically less than 1.0 ng/ml. It has an elimination half-life of about 8 hours and is primarily eliminated via renal excretion. Hepatic metabolism plays a minor role in its elimination.

**Mode of Action:** Apraclonidine binds to pre- and postsynaptic alpha-2 adrenergic receptors in the ciliary body.  Stimulation of presynaptic receptors inhibits norepinephrine release, further reducing aqueous humor production.  While some binding to alpha-1 receptors occurs, the predominant effect is mediated through alpha-2 receptor agonism.

## Dosage

### Standard Dosage

#### Adults:

For glaucoma:  Instill 1-2 drops of 0.5% apraclonidine solution in the affected eye(s) three times per day.  The maximum recommended treatment duration for this indication is one month.  For perioperative IOP control: Instill one drop of 1% apraclonidine solution in the operative eye one hour before anterior segment laser surgery and a second drop immediately after the procedure.


#### Children:

The safety and efficacy of apraclonidine have not been established in children under 21 years of age.  Use in children is generally avoided. If used, dosing must be determined by a physician.



#### Special Cases:

* **Elderly Patients:**  No specific dose adjustments are typically required based on age alone. However, close monitoring for cardiovascular effects is recommended, especially in patients with comorbidities.
* **Patients with Renal Impairment:**  Caution is advised in patients with chronic renal failure. Monitor cardiovascular parameters frequently.
* **Patients with Hepatic Dysfunction:**  Caution is advised. Closely monitor cardiovascular parameters due to potential alterations in apraclonidine metabolism.
* **Patients with Comorbid Conditions:** Use with caution in patients with severe or uncontrolled cardiovascular diseases, including uncontrolled hypertension, coronary insufficiency, recent myocardial infarction, cerebrovascular disease, and peripheral vascular diseases like Raynaud's disease or thromboangiitis obliterans.

### Clinical Use Cases

Apraclonidine is primarily indicated for short-term use in glaucoma management to delay the need for surgery and for preventing or controlling IOP spikes after anterior segment laser surgery. It is not typically utilized in other clinical settings like intubation, general surgical procedures, mechanical ventilation, ICU, or emergency situations.

### Dosage Adjustments

Dosage adjustments may be necessary based on patient response and tolerance. Patients with renal or hepatic impairment may require closer cardiovascular monitoring and potential dose reductions.

## Side Effects

### Common Side Effects

* Ocular:  Dry eyes, eye discomfort, foreign body sensation, blurred vision, tearing, redness, itching, eyelid edema, and conjunctival blanching.
* Systemic: Dry mouth, drowsiness, dizziness, headache, fatigue, and altered taste.

### Rare but Serious Side Effects

* Ocular:  Iritis, uveitis, and corneal erosion or infiltration.
* Systemic:  Hypotension, bradycardia, syncope, allergic reactions (including rash, hives, and angioedema), and depression.


### Long-Term Effects

Tachyphylaxis, a decrease in the drug's effectiveness over time, may occur with prolonged use.


### Adverse Drug Reactions (ADR)

Severe allergic reactions requiring immediate medical attention can occur.  Observe for symptoms like difficulty breathing, swelling of the face or throat, and severe skin reactions.

## Contraindications

* Hypersensitivity to apraclonidine, clonidine, or any component of the formulation.
* Concurrent use of monoamine oxidase inhibitors (MAOIs).

## Drug Interactions

* **Additive or Synergistic Effects:** Other IOP-lowering medications, systemic clonidine, central nervous system depressants (e.g., sedatives, hypnotics), beta-blockers (ophthalmic and systemic), and cardiac glycosides.
* **Antagonistic Effects:** Tricyclic antidepressants may reduce the hypotensive effect of apraclonidine.
* **CYP450 Interactions:** No significant CYP450 interactions have been reported.

## Pregnancy and Breastfeeding

Pregnancy Safety Category: C (Not recommended by some experts.  Risk cannot be ruled out).

Apraclonidine has shown embryotoxic effects in animal studies at high doses.  There are no adequate and well-controlled studies in pregnant women.  Its use during pregnancy is not recommended unless the benefits outweigh the potential risks.  It is not known if apraclonidine is excreted in human milk.  Use during breastfeeding is not recommended.

## Drug Profile Summary

* **Mechanism of Action:** Alpha-2 adrenergic agonist, decreases aqueous humor production.
* **Side Effects:**  Dry eyes, blurred vision, dry mouth, drowsiness, dizziness.  Rarely, allergic reactions and cardiovascular effects.
* **Contraindications:** Hypersensitivity, concurrent MAOI use.
* **Drug Interactions:**  Other IOP-lowering drugs, clonidine, CNS depressants, beta-blockers, cardiac glycosides, TCAs.
* **Pregnancy & Breastfeeding:** Not recommended.
* **Dosage:** Glaucoma: 0.5% solution, 1-2 drops tid. Perioperative: 1% solution, one drop before and after laser surgery.
* **Monitoring Parameters:** IOP, visual fields, cardiovascular parameters (especially in patients with renal/hepatic impairment).


## Popular Combinations

Apraclonidine is often used in combination with other topical glaucoma medications, such as beta-blockers (e.g., timolol) and prostaglandin analogs (e.g., latanoprost), to achieve additive IOP lowering.


## Precautions

General Precautions: Assess for allergies, pre-existing medical conditions, and concurrent medications.  
Specific Populations:  Caution in pregnant/breastfeeding women, children, and elderly individuals.  Monitor patients with renal or hepatic impairment. Lifestyle Considerations: Advise patients about potential drowsiness and its impact on activities requiring mental alertness.

## FAQs


### Q1: What is the recommended dosage for Apraclonidine?

A: For glaucoma: 1-2 drops of 0.5% solution three times daily in the affected eye(s) for a maximum of one month. For perioperative use: One drop of 1% solution one hour before and immediately after anterior segment laser surgery.


### Q2: What is the mechanism of action of Apraclonidine?

A: Apraclonidine primarily reduces intraocular pressure by decreasing aqueous humor production through its action as an alpha-2 adrenergic agonist.


### Q3: What are the common side effects of Apraclonidine?

A: Common side effects include dry eyes, blurred vision, foreign body sensation, dry mouth, drowsiness, dizziness, headache, and fatigue.


### Q4:  What are the contraindications for Apraclonidine use?

A: Apraclonidine is contraindicated in patients with hypersensitivity to the drug or clonidine, and in those concurrently taking monoamine oxidase inhibitors (MAOIs).



### Q5: Are there any drug interactions with Apraclonidine?

A: Yes.  Apraclonidine can interact with other IOP-lowering medications, clonidine, CNS depressants, beta-blockers, cardiac glycosides, and tricyclic antidepressants.



### Q6: Can Apraclonidine be used during pregnancy or breastfeeding?

A: Apraclonidine is generally not recommended during pregnancy or breastfeeding due to potential risks to the fetus or infant.


### Q7: What are the signs of an allergic reaction to Apraclonidine?

A: Allergic reactions can manifest as itching, rash, hives, swelling of the face or throat, difficulty breathing, and severe dizziness. Seek immediate medical attention if these occur.


### Q8: What should patients be advised regarding activities requiring mental alertness while using Apraclonidine?

A: Apraclonidine can cause drowsiness and dizziness.  Patients should be cautioned about engaging in activities that require mental alertness, such as driving or operating machinery, until the effects of the medication are known.


### Q9: How should Apraclonidine be stored?

A: Store apraclonidine ophthalmic solution below 25°C (77°F). Do not freeze. Protect from light.  Discard any unused medication after the expiration date or four weeks after opening.

